Poloxamer 407 based-nanoparticles for controlled release of methotrexate

Sofia Moura¹, Jennifer Noro¹, Patrícia Cerqueira, Carla Silva, Artur Cavaco-Paulo, Ana Loureiro*  
Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

ARTICLE INFO

Keywords:  
Poloxamer 407-based nanoparticles  
Methotrexate di-ethylated  
Methotrexate-Poloxamer 407 conjugate  
Drug release  
Cancer therapy

ABSTRACT

Poloxamer 407 (P407)-based nanoparticles were produced by the high pressure homogenization method for the encapsulation and delivery of methotrexate (MTX), aiming intravenous therapeutic applications. The surface of these nanoparticles was functionalized by conjugation of P407 with folic acid (FA) or with MTX, which served as targeting ligand agents. MTX-P407 conjugate was also developed to increase the final drug cargo. Two hydrophobic derivatives of MTX, MTX di-ethylated ester (MTX-OEt) and the ionic complex MTX-dimethyloladecylammonium bromide (MTX-DODAB) were produced and entrapped onto P407-based nanoparticles. All formulations developed revealed a monodisperse character comprising small and narrow nanoparticles (< 100 nm). P407 nanoparticles (functionalized with FA) and MTX-P407 nanoparticles, both loaded with MTX-OEt, demonstrated a slow drug release profile. The effect of lipase from Aspergillus oryzae on the hydrolysis of the linkage between the P407 and MTX, and consequent MTX release profile, was also evaluated. We observed a controlled and slow release of MTX (~50% of release after 11 days) in the presence of enzyme. These MTX-P407 nanoparticles loaded with MTX-OEt induced a great effect against Caco-2 cancer cells (~40% of cell death after 72 h of incubation), demonstrating higher efficiency than the free MTX at the same concentration.

1. Introduction

Nanomedicine has gained interest as a mean to potentiate the advantages of efficient drug delivery (Huang et al., 2018), decreasing the risk of toxicity to the normal tissues and organs of the patient (Alam et al., 2015). The clever use of nanoparticles has revolutionized how drugs are formulated and delivered (Rizvi and Saleh, 2018). Nanoparticles have been synthesized using various different methods depending of its application and type of drugs to be encapsulated (Pinto Reis et al., 2006). Loureiro and co-workers, reported a novel method based on high pressure homogenization of a biphasic system (aqueous phase and vegetable oil) to produce stable P407-based nanoparticles of small size (Loureiro et al., 2018). Poloxamers are poly(ethylene oxide) (PEO)-poly(propylene oxide) (PPO)-poly(ethylene oxide) type of block copolymers generally expressed as PEOₓ-PPOᵧ-PEOₓ (Kabanov et al., 2002b), where x and y designate the total average number of PEO and PPO repeat units, respectively (Kedar et al., 2010). This arrangement results in amphiphilic copolymers (Kabanov et al., 2002a). Reviews that address Poloxamers have explored specific structures, such as hydrogels and Poloxamer-modified particles (Bodratti and Alexandridis, 2018). Due to their lateral PEG hydrophilic chains, Poloxamers provide steric stabilization and prevention of protein adsorption, resulting in less phagocytized nanoparticles and longer half-life in the systemic circulation (Alexis et al., 2008). Another exceptional feature is that Poloxamers inhibit efflux action of P-glycoprotein (Chen et al., 2013), which is associated to multidrug resistance (MDR) (Kedar et al., 2010).

MTX is one of the most studied and effective chemotherapeutic agents available to treat many tumours and autoimmune diseases (Abolmaali et al., 2014). MTX has also been described as a dual-acting molecule, due to its high structural similarity to FA, and it can be used as targeting agent (Loureiro et al., 2016). However, limitations as toxicity and drug resistance associated to adverse side-effects, poor aqueous solubility and short circulation half-life of the free acid form of MTX have been limiting its therapeutic applications (Choi et al., 2018; Gulfam et al., 2017). To overcome these drawbacks and improve the drug efficacy and pharmacokinetics many studies have been carried out. One of the strategies is the development of prodrugs by chemical modification of the MTX. For example, MTX dodecyl ester derivative was synthetized by esterification of the α- and γ-carbonyl groups of the glutamic acid aiming to increase its lipophilic behaviour, for a higher encapsulation in a lipid formulation (Moura et al., 2011). Xie and co-workers synthetized MTX-PEG-DPPE to produce micellar nanoparticles. This MTX prodrug was used as dual-acting agent, acting simultaneously as tumour targeting ligand and as anticancer agent, revealing to be an...
interesting example of a drug delivery system (Xie et al., 2018). The amphiphilic properties of Poloxamer have also been explored on its conjugation with MTX for the production of polymeric micelles, allowing a sustained release of MTX (Ren et al., 2015).

In this work, P407-based nanoparticles were developed in order to optimize the encapsulation of MTX and its controlled delivery (Loureiro et al., 2018). Two hydrophobic MTX derivatives were developed, MTX-OEt and an ionic complex of MTX-DODAB, and encapsulated on P407-based nanoparticles. These hydrophobic derivatives revealed higher encapsulation onto P407-based nanoparticles ability compared to the commercial MTX. The conjugation of P407 with MTX was also assessed to produce nanoparticles containing MTX as a dual-acting agent and to increase the concentration of MTX on the final formulation. The biological effect of these nanoparticles against cancer cells (Caco-2) was evaluated.

2. Materials and methods

2.1. Synthesis procedures

2.1.1. Synthesis of MTX-P407 and FA-P407 conjugates

Commercial MTX was firstly converted into its carboxylic acid salt form in order to increase its water solubility. For this, MTX was suspended in water, and 2 eq. of NaOH were added. After complete solubilization of the solid the pH was neutralized. The respective MTX as sodium salt (MTX-CO$_2$Na) form was recovered after freeze-drying. Then, MTX-CO$_2$Na (40 mg, 1 eq.) and DODAB (101 mg, 2 eq.) were dissolved in a mixture of water (4 mL) and ethanol (4 mL). The suspension was then placed in a water bath at 70 °C and 700 rpm. After 70 min, the yellow solid formed was recovered by filtration and washed with water. This solid was identified as the MTX-DODAB complexed form with two units of DODAB, isolated with $\eta = 45.5\%$ of yield.

NMR (DMSO-$d_6$) $\delta$: 0.84 (t, $J = 5.6$ Hz, 12H), 1.24 (m, 128H), 1.61 (m, 9H), 1.73 (m, 3H), 3.13 (s, 3H), 3.19 (s, 12H), 3.67 (s, 1H), 4.74 (s, 2H), 6.57 (s, 2H), 6.82 (d, $J = 9.2$ Hz, 2H), 7.34 (s, 1H), 7.62 (d, $J = 8.8$ Hz, 2H), 7.67 (s, 1H), 8.35 (s, 1H), 8.57 (s, 1H) ppm.

2.1.2. Synthesis of MTX-DODAB complex

Commercial MTX was firstly converted into its carboxylic acid salt form in order to increase its water solubility. For this, MTX was suspended in water, and 2 eq. of NaOH were added. After complete solubilization of the solid the pH was neutralized. The respective MTX as sodium salt (MTX-CO$_2$Na) form was recovered after freeze-drying. Then, MTX-CO$_2$Na (40 mg, 1 eq.) and DODAB (101 mg, 2 eq.) were dissolved in a mixture of water (4 mL) and ethanol (4 mL). The suspension was then placed in a water bath at 70 °C and 700 rpm. After 70 min, the yellow solid formed was recovered by filtration and washed with water. This solid was identified as the MTX-DODAB complexed form with two units of DODAB, isolated with $\eta = 45.5\%$ of yield.

NMR (DMSO-$d_6$) $\delta$: 0.84 (t, $J = 5.6$ Hz, 12H), 1.24 (m, 128H), 1.61 (m, 9H), 1.73 (m, 3H), 3.13 (s, 3H), 3.19 (s, 12H), 3.67 (s, 1H), 4.74 (s, 2H), 6.57 (s, 2H), 6.82 (d, $J = 9.2$ Hz, 2H), 7.34 (s, 1H), 7.62 (d, $J = 8.8$ Hz, 2H), 7.67 (s, 1H), 8.35 (s, 1H), 8.57 (s, 1H) ppm.

Deuterated dimethyl sulfoxide (DMSO-$d_6$, Cortecnet, France) was used as NMR solvent and the peak solvent used as internal reference. All spectra were traced in a 400 MHz Bruker Avance III equipment. Pyridine (≥ 99.5%) was used as internal standard for the quantification of MTX. The procedure and methodology were performed as described (Guimarães et al., 2019). Signal multiplicity is given as: s (singlet), d (doublet), t (triplet) and m (multiplet).

2.3. MALDI-TOF

MALDI-TOF mass spectra were acquired on a Bruker Autoflex Speed instrument (Bruker Daltonics GmbH) equipped with a 337 nm nitrogen laser. The procedure was followed as previously described (Loureiro et al., 2018). DHB was used as matrix and the samples analysed in the linear negative mode.

2.4. Production of P407-based nanoparticles

The production of the nanoparticles was performed as previously described by Loureiro et al. (Loureiro et al., 2018). The initial formulations were prepared according to the purpose of the nanoparticles, where to an aqueous solution of P407 at 5 mg/mL in PBS (pH 7.4) was added vegetable oil (organic phase) using a 99.5/0.5 ratio (v/v), respectively. For the nanoparticles functionalized with FA at their surface, the conjugate FA-P407 was added to the aqueous phase of the initial formulation, as previously reported (Loureiro et al., 2018). Whilst for the preparation of the MTX-P407 nanoparticles, the aqueous phase was a solution of this conjugate where the concentration of the P407 was maintained at 5 mg/mL. For the entrapment of the hydrophobic derivatives of MTX (MTX-DODAB complex and MTX-OEt) in the nanoparticles, these compounds were dissolved in the vegetable oil phase applied in the initial formulation. These initial formulations were submitted to homogenization cycles at high pressures (250 and 600 bar, two stages of pressure) using a high-pressure homogenizer (APV-2000 Homogenizer from SPX, Denmark), which resulted in the nanoparticles formation. The free drug was separated from the nanoparticles using PD-10 desalting columns containing Sephadex G-25 Medium (cut-off 5 kDa) from GE Healthcare, UK. After separation, the free drug was quantified by measuring the absorbance at $\lambda_{max} = 303$ nm. Prior to cellular tests, the nanoparticles were filtered under sterile conditions using 0.22 µm polyethersulfone (PES) filter (Merck Millipore, Ireland).

2.5. Nanoparticles characterization

2.5.1. Dynamic light scattering (DLS)

The size distribution and surface charge of the produced nanoparticles were analysed by dynamic light scattering using the Malvern Zetasizer NS from Malvern Instruments, UK. The measurements were performed using PBS at pH 7.4, at 25 °C (Cerqueira et al., 2019). The concentration of P407 was kept constant at 1 mg/mL. Nanoparticles were store for more than 7 months at 4 °C and constant measurements
2.7.1. Cells and culture conditions

Caco-2 cell line was maintained in a humidified atmosphere of 5% CO2 in air at 37 °C, growing in T75 flasks. Caco-2 cells were routinely grown in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 20% (v/v) of Fetal Bovine Serum (FBS), 1% (v/v) of penicillin/streptomycin solution and 1% (v/v) of Minimum Essential Medium (MEM) non-essential amino acids.

2.7.2. Cells viability assay

Cell viability was studied using the MTS assay, as previously described (Loureiro et al., 2015a). Briefly, Caco-2 cells were seeded in 96-well tissue culture polystyrene plates at a density of 1 × 10^4 cells/well and incubated overnight to promote cell adhesion. The cells were incubated for 48 and 72 h with different concentrations of nanoparticles containing MTX and/or MTX derivatives and respective controls. After removal of all the unreacted MTX and the reactional components, the cells were incubated for 48 h at 37 °C, then the absorbance of the formazan product was read at 490 nm.

2.7.3. Synthesis of MTX-P407 conjugate

The synthesis of MTX-P407 conjugate was performed through an esterification reaction. Similarly to the previous conjugate (FA-P407) synthetized by us (Loureiro et al., 2018), the reaction was carried using DCC as coupling agent, with DMAP as base source (Scheme 1).

After removal of all the unreacted MTX and the reactional components by dialysis, the expected conjugate was isolated. The concentration of P407 and MTX in the final solution was quantified by NMR (Fig. 1). NMR is a powerful tool for quantitative determination of drugs, providing high specificity and sensitivity, having great reproducibility and automation (Guimarães et al., 2019). The results revealed a MTX concentration of 0.42 ± 0.08 mg/mL, and a P407 concentration of 29.85 ± 0.21 mg/mL. Moreover, based on the integration of the peaks corresponding to MTX and to P407 it was possible to infer 44.7% of modification of P407 with MTX. This methodology allowed, by using a single analysis, to quantify both components with high levels of reproducibility. Despite being possible to quantify MTX by absorbance analysis, no reports were found about the P407 quantification using this methodology. Thus, this technique did not seemed the ideal for the simultaneous quantification of both components on the conjugate.

In the 1H NMR spectrum of MTX-P407 conjugate (Fig. 1) is possible to observe the typical signals of MTX and P407. The patterns of all signals remained the same as in the starting materials spectra. Protons near the glutamic moiety, appear at different chemical shifts, as already observed for FA-P407 conjugate (Loureiro et al., 2018).

The molecular weight of the conjugate was also assessed by MALDI-TOF mass spectrometry (Fig. S1, Supporting information). The MALDI-TOF spectra of the MTX-P407 conjugate showed a m/z of 13372.242 Da, revealing that only one molecule of MTX was conjugated with each molecule of P407 (MWaverage of MTX-P407 conjugate – MWaverage of P407 = 194.467 Da). The mass difference detected was lower than the MWaverage of MTX obtained by MALDI-TOF analysis (431.783 Da – data not shown). Considering that the spectra was acquired in negative linear mode, only average masses were detected, which might explain the differences obtained between the monomer and the conjugate (Loureiro et al., 2019).

The level of P407 modification inferred by MALDI-TOF analysis (45.0%) was similar to the one obtained by 1H NMR (44.7%).

3.2. Synthesis of hydrophobic MTX derivatives

The commercial MTX presents very low solubility either in organic or aqueous solvents. Two hydrophobic MTX derivatives (MTX-DODAB complex and MTX-OEt) were produced (Scheme 2), aiming to improve its lipophilic character and increase its concentration on the organic phase (vegetable oil) of the P407-based nanoparticles.

The ionic complex between MTX and DODAB was synthetized as described in section 2.1.2. We found the addition of two equivalents of DODAB crucial for the complex formation, resulting in two units of the quaternary amine complexed with both carboxylic groups of MTX. The number of DODAB units was determined by 1H NMR (Fig. 2) and ESI (m/z = 1552 – data not shown). The ionic complex was isolated after precipitation in water (n = 45%). The 1H NMR spectra of the ionic complex showed all the typical peaks of MTX and DODAB. The MTX peaks reveal the same pattern as previously reported (Cerqueira et al., 2019), with small chemical shifts, especially of the protons g, h and j/i, which are close to the complexed carboxylic groups.

MTX-OEt was produced as described by Cerqueira et al. (Cerqueira et al., 2019) (Scheme 2) and its encapsulation in P407-based nanoparticles was tested without any further modification. We tested the encapsulation of this prodrug due to this hydrophobic nature but also due to its promising biological effect against cancer cells (Caco-2 cell line), previously described by Cerqueira et al. (Cerqueira et al., 2019).

3.3. Production and characterization of the P407-based nanoparticles

P407 features several advantages like biocompatibility and high solubility in aqueous solvents and for these reasons has been extensively applied on the production of nanodevices for diverse
Scheme 1. Reactional scheme for the synthesis of MTX-P407 conjugate.

Fig. 1. $^1$H NMR spectrum of MTX-P407 conjugate in DMSO-$d_6$. The peaks labelled in lowercase blue letters correspond to the protons indicated in the structures of MTX (letters from a to j) and P407 (letters k and l). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Scheme 2. Reactional schemes for the synthesis of MTX-DODAB ionic complex and MTX-OEt.
applications (Breitenbach et al., 2017). Loureiro et al. described the use of the high pressure homogenization method to produce P407-based nanoparticles with suitable properties for therapeutic applications (Loureiro et al., 2018). These nanoparticles showed potentiality for intravenous (IV) administration (small and stealth nanoparticles) and demonstrated the ability to be efficiently internalized by cancer cells.

Nanoparticles larger than 100 nm can be easily cleared-off by macrophages and other mononuclear phagocyte system (MPS) cells and cleared from circulation by phagocytosis (Zahr et al., 2006). Additionally, nanoparticles below 10 nm have a higher tendency to be excreted by the kidneys (Danaei et al., 2018). Therefore, the range between 10 nm and 100 nm is considered the most appropriate for IV administration to reach the target cells (Loureiro et al., 2015b). Populations presenting polydispersity values (PDI) ≤ 0.2 are considered acceptable for polymer-based nanoparticles (Danaei et al., 2018), representing monodisperse populations of nanoparticles (Cun et al., 2010; Hornig et al., 2009) with the ideal physicochemical conditions for IV administration.

In this work, empty P407 based-nanoparticles functionalized or nonfunctionalized with FA were produced and their performance was compared with the nanoparticles produced using the MTX-P407 conjugate. The physicochemical characterization of the nanoparticles performed by DLS and NTA techniques (Table 1) indicate that these nanoparticles present suitable characteristics for IV administration. All formulations revealed similar small size (91–98 nm) and monodisperse populations (PDI < 0.2), indicating that the MTX-P407 conjugate did not influence negatively the nanoparticles formation, leading, on the other hand, to the formation of higher concentration of particles (Table 1, NTA results).

3.4. Encapsulation of MTX-derivatives in P407-based nanoparticles

The hydrophobic derivatives of MTX (MTX-DODAB and MTX-OEt), as well as the unmodified MTX, were encapsulated in the produced nanoparticles (Table 2). Due to its poor solubility in organic or aqueous media, the lowest final drug concentration was obtained when encapsulating unmodified MTX. As expected, the highest amount of MTX/MTX derivative on the final formulation was achieved for the MTX-P407 nanoparticles loaded with MTX-OEt. The amount of MTX on the loaded formulations derives from MTX linked to P407 at the nanoparticles’ shell, and from MTX-OEt entrapped onto the nanoparticles. For this reason, the molar concentration of MTX/MTX derivative was not inferred since the formulation is composed by two different types of MTX which cannot be distinguished using the indirect absorbance quantification method applied herein.

From Table 2 one can also highlight that all the loaded nanoparticles reveal sizes similar to the empty nanoparticles (Table 1) corresponding to monodisperse populations (< 0.150). All formulations have neutral surface charge (zeta-potential values around 0 ± 2 mV). The neutral and hydrophilic surface, conferred by the presence of PEG chains of the P407, can lead to a longer half-life in the blood circulation (Zahr et al., 2006), which in turns the developed formulations suitable for IV therapeutic applications. The formulations revealed also high stability along time, demonstrated by the maintenance of their physicochemical properties even after 7 months of storage (data not shown).

Considering the highest concentration of drug at the final formulations, the P407 nanoparticles encapsulating MTX-OEt (functionalized with FA for a specific delivery) or the MTX-P407 nanoparticles encapsulating MTX-OEt were chosen for posterior assays.
3.5. Release profile of MTX from P407-based nanoparticles

The in vitro release of MTX from the P407-based nanoparticles loaded with MTX-OEt was evaluated at 37 °C through dialysis of the MTX from the bulk formulations and after incubation of the MTX-P407 nanoparticles with a lipase (Fig. 3). The release of MTX was performed at two different pHs, at physiological pH (7.4, full line) and at acidic pH, mimicking the tumor microenvironment (6.5, dash line) (Cao et al., 2016). As P407 is a non-ionic polymer, it is expected that small differences in the buffer pH would not affect the stability of the nanoparticles, and therefore their release profile.

Many nanodevices have been studied for the encapsulation and release of MTX, however most of the strategies revealed the release of all the drug content after 48 h (Karasulu et al., 2007; Nogueira et al., 2016; Zhao et al., 2016).

The P407-based nanoparticles tested, as functionalized with FA or prepared with MTX-P407 conjugate, revealed a similar slow release profile, at both pH tested, as depicted in Fig. 3. As P407 is a non-ionic polymer it would be expected that small differences in the buffer pH would not affect the stability of the nanoparticles, and therefore their release profile.

FA-tagged P407 nanoparticles showed the highest MTX release at both pH tested (> 50% after 272 h, Fig. 3, red lines) than the nanoparticles prepared using the MTX-P407 conjugate (= 30% after 272 h, Fig. 3, black lines). The data is presented in terms of MTX percentage release relatively to the total amount in the final formulations. Considering that MTX-P407 nanoparticles are composed by a higher amount MTX/MTX derivative (entrapped MTX-OEt and MTX conjugated to P407), when comparing with the FA-tagged P407 nanoparticles, a lower percentage of release after 272 h is observed. We might speculate that the MTX-OEt present in the hydrophobic core of both formulations is more easily released from the nanoparticles than the MTX covalently linked to P407, which would be more hardly disrupted. In this way, the FA-tagged nanoparticles release a higher percentage of MTX, than the formulations composed by the MTX-P407 conjugate.

In a biological environment, the nanoparticles are susceptible to degradation by a panoply of hydrolytic enzymes (Rios-Ramírez, 2013), being esterases an example of enzymes involved in drug metabolism (Fukami and Yokoi, 2012). In this way, the role of lipase from Aspergillus oryzae on the MTX-P407 conjugate hydrolysis was undertaken (Fig. 3, blue lines). We chose this lipase based on its affinity for large substrates, such as acylglycerols (Toida et al., 1995). During all the dialysis processing, the enzyme remained stable (no significant activity loss until 1 month at 37 °C). At pH 7.4, MTX-P407 nanoparticles loaded with MTX-OEt, even after incubation with lipase, revealed a lower MTX release (= 38% after 272 h) than observed for the FA-tagged P407 nanoparticles. At pH 6.5, the enzyme action was responsible for an

![Fig. 3. Release over time of MTX from the P407 nanoparticles functionalized with FA and MTX-P407 nanoparticles, both loaded with MTX-OEt (red and black lines, respectively), and release of MTX from the MTX-P407 nanoparticles in the presence of lipase from Aspergillus oryzae (blue lines). Physiological pH (7.4, full line) and acidic pH (6.5, dash line). The values are a mean of two independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](image)

---

### Table 1

Physicochemical characterization of P407-based nanoparticles functionalized and nonfunctionalized with FA and of MTX-P407 nanoparticles, measured by DLS and NTA. Values represent the mean ± SD of two independent experiments.

<table>
<thead>
<tr>
<th>System</th>
<th>Z-average (nm)</th>
<th>Polydispersity Index (PDI)</th>
<th>Mean (nm)</th>
<th>SD (nm)</th>
<th>Conc. particles (particles/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DLS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P407 nanoparticles</td>
<td>98.4 ± 2.9</td>
<td>0.176 ± 0.041</td>
<td>98.0 ± 10.1</td>
<td>43.5 ± 16.8</td>
<td>2.8 ± 0.38 (E 12)</td>
</tr>
<tr>
<td>FA-tagged P407</td>
<td>92.3 ± 3.7</td>
<td>0.118 ± 0.001</td>
<td>98.8 ± 8.4</td>
<td>43.5 ± 15.1</td>
<td>2.7 ± 0.23 (E 12)</td>
</tr>
<tr>
<td>MTX-P407 nanoparticles</td>
<td>91.3 ± 24.4</td>
<td>0.122 ± 0.003</td>
<td>97.0 ± 5.7</td>
<td>39.0 ± 3.9</td>
<td>5.1 ± 0.61 (E 12)</td>
</tr>
<tr>
<td><strong>NTA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P407 nanoparticles</td>
<td>98.0 ± 10.1</td>
<td>0.161 ± 0.033</td>
<td>95.0 ± 3.2</td>
<td>34.0 ± 1.5</td>
<td>4.2 ± 0.60 (E 12)</td>
</tr>
<tr>
<td>FA-tagged P407</td>
<td>92.3 ± 3.7</td>
<td>0.118 ± 0.001</td>
<td>98.8 ± 8.4</td>
<td>43.5 ± 15.1</td>
<td>2.7 ± 0.23 (E 12)</td>
</tr>
<tr>
<td>MTX-P407 nanoparticles</td>
<td>91.3 ± 24.4</td>
<td>0.122 ± 0.003</td>
<td>97.0 ± 5.7</td>
<td>39.0 ± 3.9</td>
<td>5.1 ± 0.61 (E 12)</td>
</tr>
<tr>
<td><strong>Table 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

Physicochemical characterization of the nanoparticles (evaluated by DLS) and final drug concentration in the formulations. Values represent the mean ± SD of two independent experiments.

<table>
<thead>
<tr>
<th>P407-based nanoparticles</th>
<th>MTX encapsulated</th>
<th>Z-average (d.nm)</th>
<th>PDI</th>
<th>[MTX/MTX derivatives] at the final formulations*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Z-average (nm)</td>
<td></td>
<td>Conc. particles (particles/mL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mg/mL</td>
</tr>
<tr>
<td>P407</td>
<td>Unmodified MTX</td>
<td>97.3 ± 10.8</td>
<td>0.105 ± 0.020</td>
<td>0.009 ± 0.004</td>
</tr>
<tr>
<td>P407</td>
<td>MTX-DODAB</td>
<td>94.7 ± 4.1</td>
<td>0.094 ± 0.013</td>
<td>0.066 ± 0.001</td>
</tr>
<tr>
<td>FA-tagged P407</td>
<td>MTX-DODAB</td>
<td>95.1 ± 7.9</td>
<td>0.099 ± 0.008</td>
<td>0.067 ± 0.001</td>
</tr>
<tr>
<td>P407</td>
<td>MTX-OEt</td>
<td>86.7 ± 6.7</td>
<td>0.096 ± 0.013</td>
<td>0.041 ± 0.018</td>
</tr>
<tr>
<td>FA-tagged P407</td>
<td>MTX-OEt</td>
<td>86.1 ± 1.7</td>
<td>0.096 ± 0.023</td>
<td>0.032 ± 0.006</td>
</tr>
<tr>
<td>MTX-P407</td>
<td></td>
<td>91.3 ± 24.4</td>
<td>0.122 ± 0.003</td>
<td>0.031 ± 0.005</td>
</tr>
<tr>
<td>MTX-P407</td>
<td>MTX-OEt</td>
<td>84.0 ± 12.7</td>
<td>0.132 ± 0.003</td>
<td>0.046 ± 0.003</td>
</tr>
</tbody>
</table>

* Concentration of drug in the nanoparticles after dilution of 1.4x in the PD-10 desalting columns.
** The molar concentration was also calculated because the MTX-DODAB complex presents a very high molecular weight (1554.52 g/mol) comparatively to the MTX (454.44 g/mol) and the MTX-OEt (510.55 g/mol), resulting in a great difference on the molar concentration.
*** Not possible to determine.
increase of the MTX release from the MTX-P407 nanoparticles loaded with MTX-OEt to the levels obtained for the FA-tagged P407 nanoparticles (≈50% after 272 h of incubation).

The presence of lipase incremented only 10% (pH = 7.4) and 15% (pH = 6.5) of MTX release from MTX-P407 nanoparticles. Considering the low release increment promoted by lipase, which in theory would break the linkage between P407 and MTX, one might speculate that the MTX-P407 formulations are composed mainly by MTX-OEt. This MTX derivative, at the time of particles formation, is dissolved in vegetable oil being entrapped onto the hydrophobic core, which in turns its release slow, as in absence or in presence of enzyme.

Both nanoparticles (FA-tagged P407 and MTX-P407 nanoparticles) revealed a controlled and sustained drug release demonstrating potentiality to serve as release matrices, reducing the dose frequency and increasing the patient compliance.

3.6. Biological effect of P407-based nanoparticles loaded with MTX-OEt

Previous studies revealed that P407-based nanoparticles (up to 900 µg/mL) did not induce cytotoxicity in immortalized human normal cells, even after 72 h of incubation (Loureiro et al., 2018). For this reason, we can consider that these nanoparticles are not harmful to normal cells, being promising candidates for therapeutic applications. In order to evaluate the biological effect of the P407-based nanoparticles loaded with MTX-OEt (functionalized or not with FA), the cell viability of cancer cells was assessed. Caco-2 cell line was chosen for the biological evaluation since it endogenously express folate receptor (FR) (Doucette and Stevens, 2001).

The results demonstrated that, as expected, empty nanoparticles (with or without FA) did not induce a significant loss of cell viability (Fig. 4). The free prodrug (MTX-OEt) or loaded into the nanoparticles displayed very similar effect on the cell viability (≈70%), confirming the ability of nanoparticles to release the MTX derivative when internalized by the cells. The FA-tagged nanoparticles loaded with 5 µg/mL of MTX-OEt showed a more pronounced biological effect against cancer cells, comparing with the effect of the same concentration of free MTX-OEt (but not statistically significant). We might deduce that these FA-tagged nanoparticles were recognized by the FR at the surface of Caco-2 cells being internalized by FR-mediated endocytosis, releasing further the drug as intended.

The biological effect of the P407-based nanoparticles loaded with MTX-OEt was not significant due to the low concentration of drug applied. In order to increase the total concentration of drug applied (to 8 µg/mL) in Caco-2 cells, the biological effect of the MTX-P407 nanoparticles was also evaluated. Fig. 5 shows the Caco-2 cell viability after 48 and 72 h of incubation with: empty MTX-P407 nanoparticles; MTX-P407 nanoparticles loaded with MTX-OEt; MTX-P407 conjugate; and the two types of MTX (unmodified MTX and MTX-OEt), at the same concentration (8 µg/mL), compared with cells (negative control) and cells incubated with 30% (v/v) of DMSO (death control), determined by MTS assay. Values are the mean ± SD of two independent experiments. Statistical significant differences from the negative control are indicated as: *P-value < 0.05; **P-value < 0.01 and ***P-value < 0.0001.

![Fig. 4. Caco-2 cell viability after 48 h of contact with P407-based nanoparticles (functionalized or nonfunctionalized with FA) containing or not 5 µg/mL of MTX-OEt and with the MTX derivative alone at the same concentration, compared with cells (negative control) and cells incubated with 30% (v/v) of DMSO (death control), determined by MTS assay. Values are the mean ± SD of two independent experiments. Statistical significant differences from the negative control are indicated as: * P-value < 0.05 and ** P-value < 0.0001. Values of FA-P407 nanoparticles + MTX-OEt and MTX-OEt alone are not statistically significant.](image1)

![Fig. 5. Caco-2 cell viability after 48 and 72 h of contact with: empty MTX-P407 nanoparticles; MTX-P407 nanoparticles loaded with MTX-OEt; MTX-P407 conjugate; and the two types of MTX (unmodified MTX and MTX-OEt), at the same concentration (8 µg/mL), compared with cells (negative control) and cells incubated with 30% (v/v) of DMSO (death control), determined by MTS assay. Values are the mean ± SD of two independent experiments. Statistical significant differences from the negative control are indicated as: *P-value < 0.05; **P-value < 0.01 and ***P-value < 0.0001.](image2)
4. Conclusions

P407-based nanoparticles loaded with different MTX derivatives were successfully produced. These nanoparticles remained stable for more than 7 months of storage, maintaining their physicochemical properties suitable for IV therapeutic applications. The encapsulation of two hydrophobic MTX derivatives (MTX-OEt and MTX-DODAB) into the hydrophobic core of the nanoparticles revealed MTX-OEt as the best prodrug to increase the final drug cargo on the developed formulations. The P407-based nanoparticles loaded with MTX-OEt revealed a slow drug release profile, which confers a great advantage relatively to many nanodevices recently studied for the encapsulation and release of MTX. MTX-P407 nanoparticles loaded with MTX-OEt showed a great biological effect against cancer cells, demonstrating to be more effective than the same concentration of free MTX. All these findings allow us to envisage the IV therapeutic application of these nanoparticles in order to potentiate the MTX therapeutic effect and overcome its several limitations. Thus, the developed nanoparticles demonstrated several potentialities to be implemented as a drug delivery system in cancer therapy.

CRediT authorship contribution statement

Sofía Moura: Investigation, Formal analysis, Writing - original draft. Jennifer Noro: Investigation, Formal analysis, Writing - original draft. Patricia Cerqueira: Investigation. Carla Silva: Conceptualization, Writing - review & editing. Artur Cavaco-Paulo: Conceptualization, Resources, Supervision, Funding acquisition. Ana Loureiro: Conceptualization, Methodology, Validation, Writing - review & editing, Supervision, Project administration.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2019 unit and BioTechNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. The authors also thanks to FCT for funding their scholarship: Jennifer Noro (SRFH/BD/121673/2016) and Carla Silva (SRFH/IF/00186/2015). This work has also received funding from the European Union Horizon 2020 research and innovation program under grant agreement NMP-06-2015-683356 FOLSMART.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijpharm.2019.118924.

References


Pinto Reis, C., Neufeld, R.J., Ribeiro, A.J., Veiga, F., 2006. Nanoencapsulation I. Methods and Technology (FCT) under the scope of the strategic funding of UID/.BIO/04469/2019 unit and BioTechNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. The authors also thanks to FCT for funding their scholarship: Jennifer Noro (SRFH/BD/121673/2016) and Carla Silva (SRFH/IF/00186/2015). This work has also received funding from the European Union Horizon 2020 research and innovation program under grant agreement NMP-06-2015-683356 FOLSMART.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijpharm.2019.118924.
